Hudson Bay Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hudson Bay Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,907,386	Closed	-$221M	–	1007
2023 Q3	$221M	Buy	1,907,386 +695,062	+57%	+$74.7M	1.73%	11
2023 Q2	$125M	Sell	1,212,324 -403,101	-25%	-$42.5M	0.91%	32
2023 Q1	$176M	Buy	1,615,425 +898,069	+125%	+$99.3M	1.45%	12
2022 Q4	$81.6M	Buy	717,356 +707,356	+7,074%	+$58.8M	0.84%	28
2022 Q3	$619K	Buy	+10,000	New	+$699K	0.01%	882
2018 Q1	–	Sell	-50,000	Closed	-$730K	–	920
2017 Q4	$730K	Sell	50,000 -175,000	-78%	-$2.46M	0.02%	413
2017 Q3	$2.85M	Sell	225,000 -25,000	-10%	-$318K	0.07%	213
2017 Q2	$2.97M	Buy	+250,000	New	+$3.11M	0.06%	279

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Hudson Bay Capital Management's HZNP Position: Q4 2023 in Review

Hudson Bay Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,907,386 shares — an estimated $221M sold.

Hudson Bay Capital Management first reported a position in HZNP in Q2 2017 and held it in 8 quarters. The position peaked at $221M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Hudson Bay Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Hudson Bay Capital Management sold 1,907,386 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $221M.
Hudson Bay Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017 and held it in 8 quarters.
Hudson Bay Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $221M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Hudson Bay Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.